Try our Advanced Search for more refined results

Teva Again Tells High Court To Nix Claim Construction Rule

By Vin Gurrieri (September 16, 2014, 1:41 PM EDT) -- Teva Pharmaceuticals USA Inc. has urged the U.S. Supreme Court to ignore Sandoz Inc. and Mylan Inc.'s argument to uphold a ruling that found several patents for Teva's multiple sclerosis drug Copaxone invalid, saying that the Federal Circuit's practice of reviewing claim constructions fresh on appeal is incorrect....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!